LARIMAR THERAPEUTICS INC (LRMR) Stock Price, Forecast & Analysis
NASDAQ:LRMR • US5171251003
LRMR Key Statistics, Chart & Performance
The current stock price of LRMR is 5.31 USD. In the past month the price increased by 48.74%. In the past year, price increased by 75.25%.
LRMR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LRMR. When comparing the yearly performance of all stocks, LRMR is one of the better performing stocks in the market, outperforming 93.51% of all stocks.
LRMR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LRMR. LRMR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LRMR Financial Highlights
Over the last trailing twelve months LRMR reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS decreased by -67.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.46% | ||
| ROE | -94.94% | ||
| Debt/Equity | 0 |
LRMR Forecast & Estimates
17 analysts have analysed LRMR and the average price target is 15.5 USD. This implies a price increase of 191.98% is expected in the next year compared to the current price of 5.31.
LRMR Ownership
LRMR Latest News, Press Relases and Analysis
LRMR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 397.113B | ||
| AMGN | AMGEN INC | 17.23 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.61 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LRMR
Company Profile
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 65 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Company Info
LARIMAR THERAPEUTICS INC
Three Bala Plaza East. Suite 506
Bala Cynwyd PENNSYLVANIA 19004 US
CEO: Carole Ben-Maimon
Employees: 65
Phone: 18445119056
LARIMAR THERAPEUTICS INC / LRMR FAQ
What does LRMR do?
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 65 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
What is the current price of LRMR stock?
The current stock price of LRMR is 5.31 USD. The price decreased by -3.8% in the last trading session.
Does LRMR stock pay dividends?
LRMR does not pay a dividend.
What is the ChartMill rating of LARIMAR THERAPEUTICS INC stock?
LRMR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of LRMR stock?
LARIMAR THERAPEUTICS INC (LRMR) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of LRMR stock?
LARIMAR THERAPEUTICS INC (LRMR) has a market capitalization of 441.21M USD. This makes LRMR a Small Cap stock.